Healthcare Industry News:  chronic lymphocytic leukemia 

Biopharmaceuticals Personnel

 News Release - January 28, 2008

Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology

SAN DIEGO, Jan. 28 (HSMN NewsFeed) -- Cylene Pharmaceuticals has appointed Dr. Kenna Anderes to its management team. Dr. Anderes, who brings 17 years of life sciences research experience with a focus on cancer biology research, will serve as Vice President of Cancer Biology. With Cylene's most advanced compound, quarfloxin (CX-3543), now in Phase II development, Dr. Anderes will be leading Cylene's biology and pre-clinical research teams to advance other targeted small molecule oncology compounds into the clinic during 2008.

"I am excited about the opportunity to advance more of Cylene's novel drug candidates into the clinic," said Dr. Anderes. "These compounds are orally available and have the potential to become effective and convenient therapeutics for cancers that currently lack effective, patient-friendly treatments."

Dr. Anderes joined Cylene from Pfizer, Inc., where she had led large project teams in oncology and cancer biology research over the past twelve years. Prior to her tenure at Pfizer, Dr. Anderes held several group leader and senior scientist positions at major biotechnology and pharmaceutical companies, such as Warner Lambert and Agouron.

"Dr. Anderes has the ideal background and experience to accelerate and expand our product pipeline," said Dr. William G. Rice, Cylene's President and Chief Executive Officer. "Her expertise in cancer biomarkers and imaging, as well as her leadership experience in pharmaceutical research, will enable her to make meaningful contributions to our management team."

Dr. Anderes earned a Ph.D. in pharmacology from the Southern Illinois University School of Medicine, and she performed a postdoctoral research fellowship in pharmacology at the University of California San Diego.

About Cylene Pharmaceuticals, Inc.

Cylene Pharmaceuticals is a private company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening cancers. Using its proprietary Ribosomal RNA Biogenesis Inhibition Technology (RABIT(TM)) to design molecules that combat drug-resistant forms of cancer, Cylene has created multiple product candidates in different stages of development. Cylene's most advanced cancer agent, quarfloxin (CX-3543), is a ribosomal RNA Biogenesis Inhibitor (RBI) in Phase II clinical development in patients having chronic lymphocytic leukemia and in late-stage Phase I development in patients having solid tumors. More information can be found at http://www.cylenepharma.com.


Source: Cylene Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.